Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Multi-centre one year trial for patients who have rising PSA while on Casodex 50mg daily
dose. Casodex dosage escalated to 150 mg tablet daily. Treatment will be continued until
patient demonstrates clinical benefit at one year, PSA progression, toxicity, or withdrawal.
Treatment will be continued after one year if patient demonstrates continued clinical
benefit.